NADPH Oxidase–driven Oxidative Profile in Adult Attention-deficit/Hyperactivity Disorder: NOX2/NOX4 Activation and Lipid Peroxidation
Clinical Psychopharmacology and Neuroscience · 30.11.2026 · 24 (4) · 809-820
DOI: 10.9758/cpn.26.1417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Psychopharmacology and Neuroscience, online erschienen am 24.03.2026. Verfasst von Gülsüm Zuhal Kamış und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Ankara Bilkent City Hospital, Ankara, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Ankara Bilkent City Hospital, Ankara, Türkiye.
- Department of Psychiatry, Van Yüzüncü Yıl University Faculty of Medicine, Van, Türkiye.
- Department of Biochemistry, Van Yüzüncü Yıl University Faculty of Medicine, Van, Türkiye.
ORCID-Profile: Gülsüm Zuhal Kamış, Faruk Kurhan, Hamit Hakan Alp
Zitieren
APA
Kamış, G. Z., Kurhan, F., & Alp, H. H. (2026). NADPH Oxidase–driven Oxidative Profile in Adult Attention-deficit/Hyperactivity Disorder: NOX2/NOX4 Activation and Lipid Peroxidation. Clinical Psychopharmacology and Neuroscience, 24(4), 809-820. https://doi.org/10.9758/cpn.26.1417
Vancouver
Kamış GZ, Kurhan F, Alp HH. NADPH Oxidase–driven Oxidative Profile in Adult Attention-deficit/Hyperactivity Disorder: NOX2/NOX4 Activation and Lipid Peroxidation. Clinical Psychopharmacology and Neuroscience. 2026;24(4):809-820. doi:10.9758/cpn.26.1417
BibTeX
@article{Kam2026,
author = {Kamış, Gülsüm Zuhal and Kurhan, Faruk and Alp, Hamit Hakan},
title = {NADPH Oxidase–driven Oxidative Profile in Adult Attention-deficit/Hyperactivity Disorder: NOX2/NOX4 Activation and Lipid Peroxidation},
journal = {Clinical Psychopharmacology and Neuroscience},
year = {2026},
volume = {24},
number = {4},
pages = {809--820},
doi = {10.9758/cpn.26.1417}
}
EUVIMED